

Global Migraine Drugs Market (By Drugs - Triptan, CGRP, Acetylcholine Inhibitors/ Neurotoxins & Others; Nations-The US, the UK, Germany, France, Italy, Spain and Japan) - Outlook 2025

<https://marketpublishers.com/r/GB7CC78C693EN.html>

Date: August 2019

Pages: 100

Price: US\$ 1,800.00 (Single User License)

ID: GB7CC78C693EN

Abstracts

INDUSTRY INSIGHTS

According to a new report by Rockville Research, the global migraine therapeutics market is estimated to be valued at US\$ 7 billion in the year 2025, growing at a CAGR of 15.2% in the period 2019 to 2025. Growth of the market is driven by factors such as increasing incidences of migraine, rising female population, patent expiration and stressed lifestyle.

Migraine is a complex debilitating neurological disorder which is often characterized by recurrent severe headaches in one side of the head. It is generally preceded by sensory warning signs and other symptoms such as sensitivity to light and noise, nausea, vomiting, dizziness, etc.

Migraine therapeutics market is expected to witness advent of first in-class novel migraine drugs especially meant for patients unresponsive to triptans or ones at risk of cardiovascular disorders. Allergan's ubrogepant and Eli Lilly's Lasmiditan are one of the leading migraine drugs based on novel mechanism of action.

REPORT SCOPE

This report "Global Migraine Therapeutics Market [By Drug Classes - Triptan, CGRP, Acetylcholine Inhibitors/Neurotoxins, Others; By Region – North America (The US), Europe (The UK, Germany, France, Italy & Spain) and Asia Pacific (Japan) - Outlook

2025]” provides a detailed analysis of the global migraine therapeutics market from qualitative and quantitative outlooks during the forecast period across various therapeutic classes. It also provides coverage on market dynamics with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market.

Parameter Description

Base year 2009

Forecast period 2019 - 2025

Market sizing Revenue in US\$ Billions & CAGR for the period 2019 to 2025

Country coverage G7 Nations - The US, The UK, Germany, France, Italy, Spain & Japan

Vendor scope Eli Lilly & Company, Teva Pharmaceutical Industries, Alder Biopharmaceuticals, Amgen Inc., AbbVie Inc. & Pfizer Inc.

Report coverage Revenue forecast, market share analysis, company analysis, competitive landscape, market growth drivers, market restraints, market trends and company profiles

SEGMENTS COVERED

The report provides revenue forecasts for global, regional and country levels. It also provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. For the purpose of research, Rockville Research has segmented global migraine therapeutics market report has been segmented on the basis of drug classes and region:-

Therapeutic Class Outlook, Revenue (2017 – 2025E, US\$ Billions)

Triptan

CGRP

Acetylcholine Inhibitors/Neurotoxins

Others

Regional Outlook, Revenue (2017 – 2025E, US\$ Billions)

North America

Europe

Asia Pacific

Country Outlook, Revenue (2017 – 2025E, US\$ Billions)

The US

The UK

Germany

France

Italy

Spain

Japan

Vendors Outlook, Revenue (2013 – 2022E, US\$ Billions)

Eli Lilly & Company

Teva Pharmaceutical Industries

Alder Biopharmaceuticals

Amgen Inc.

AbbVie Inc.

Pfizer Inc.

Target Audience

Migraine Drug Manufacturers

Chemical Suppliers

End Users

Research Professionals

Healthcare Consultancies

Regulatory Bodies

Key questions answered in the report

Historical market size of migraine therapeutics from 2009 to 2018 in US\$ Billions.

Projected market growth in the forecasted period 2019 to 2025 with estimated revenue for each year in US\$ Billions.

Revenue forecasts of major migraine therapeutics in the period 2016 to 2025 in US\$ Billions.

Regional and country of migraine therapeutics in the period 2017 to 2025 in US\$ Billions.

Market drivers, restraints and industry trends that has impact on revenue.

Profiling of major companies with detailed analysis of major migraine

therapeutics approved for marketing as well as in pipeline.

Customization

We provide customization of the study in order to provide specific information as sought by the client.

Contents

1. EXECUTIVE SUMMARY

2. RESEARCH METHODOLOGY

3. MIGRAINE

3.1 Overview

- 3.1.1 Types of Migraine
- 3.1.2 Stages of Migraine
- 3.1.3 Symptoms of Migraine
- 3.1.4 Diagnosis

3.2 Treatment

- 3.2.1 Abortive Medications
- 3.2.2 Preventive Medications
- 3.2.3 Alternative Medicine

4. MARKET ANALYSIS

4.1.1 Market Sizing (Actual & Forecasted)

4.2 Market Share Analysis

- 4.2.1 Market Share by Treatment Drugs
- 4.2.2 Market Share by Drug Type
- 4.2.3 Market Share by Nations

5. MARKET SEGMENTATION BY DRUG CLASS

5.1 Triptan

- 5.1.1 Overview
- 5.1.2 Market Sizing (Actual & Forecasted)

5.2 CGRP

- 5.2.1 Overview
- 5.2.2 Market Sizing (Actual & Forecasted)

5.3 Acetylcholine Inhibitors/ Neurotoxins

- 5.3.1 Overview
- 5.3.2 Market Sizing (Actual & Forecasted)

5.4 Others

- 5.4.1 Overview

5.4.2 Market Sizing (Actual & Forecasted)

6. MIGRAINE MARKET REGIONAL ANALYSIS

6.1 North America

6.1.1 The US

6.1.1.1 Market Sizing (Actual & Forecasted)

6.2 Europe

6.2.1 France

6.2.1.1 Market Sizing (Actual & Forecasted)

6.2.2 Germany

6.2.2.1 Market Sizing (Actual & Forecasted)

6.2.3 Italy

6.2.3.1 Market Sizing (Actual & Forecasted)

6.2.4 Spain

6.2.4.1 Market Sizing (Actual & Forecasted)

6.2.5 The UK

6.2.5.1 Market Sizing (Actual & Forecasted)

6.3 Asia Pacific

6.3.1 Japan

6.3.1.1 Market Sizing (Actual & Forecasted)

7. MARKET DYNAMICS

7.1 Industry Trends & Development

7.1.1 Anti-CGRP Drugs Pipeline

7.1.2 Launch of Cheaper Migraine Drugs

7.1.3 Emphasis on Preventative Migraine Treatment

7.1.4 Advent of Novel Migraine Drugs

7.1.5 Neuromodulation Devices for Migraine Treatment

7.2 Growth Drivers

7.2.1 Prevalence of Migraine

7.2.2 Rising Female Population

7.2.3 Patent Expirations

7.2.4 Stressed Lifestyle

7.3 Challenges

7.3.1 Poor Efficacy of Drugs

7.3.2 Regulatory Hurdle

7.3.3 Low Diagnosis Rate

7.3.4 Preference for Alternative Therapies

8. COMPETITIVE LANDSCAPE

9. COMPANY PROFILE

9.1 Eli Lilly & Company

9.2 Teva Pharmaceutical Industries

9.3 Alder Biopharmaceuticals

9.4 Amgen Inc.

9.5 AbbVie Inc.

9.6 Pfizer Inc.

I would like to order

Product name: Global Migraine Drugs Market (By Drugs - Triptan, CGRP, Acetylcholine Inhibitors/ Neurotoxins & Others; Nations-The US, the UK, Germany, France, Italy, Spain and Japan) - Outlook 2025

Product link: <https://marketpublishers.com/r/GB7CC78C693EN.html>

Price: US\$ 1,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB7CC78C693EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970